EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Conserved immuno‐collagenic subtypes predict response to immune checkpoint blockade

Jie Mei iD, Yun Cai, Rui Xu, Qing Li, Jiahui Chu, Zhiwen Luo, Yaying Sun, Yuxin Shi, Junying Xu, Di Li, Shuai Liang, Ying Jiang und 8 weitere

Cancer Communications · 2024

DOI: 10.1002/cac2.12538 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Communications, 2024. Verfasst von Jie Mei und 19 weiteren Autor:innen. Beteiligte Einrichtung: Department of Oncology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu, P. R. China. Hauptthemen laut MEDLINE: Immune Checkpoint Inhibitors, Neoplasms, Collagen. Die Arbeit wurde bisher 38-mal zitiert (Crossref) und nennt 66 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: National Key Research and Development Program of China, National Natural Science Foundation of China, High-level Innovation Team of Nanjing Medical University.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Immune checkpoint blockade (ICB) has revolutionized the treatment of various cancer types. Despite significant preclinical advancements in understanding mechanisms, identifying the molecular basis and predictive biomarkers for clinical ICB responses remains challenging. Recent evidence, both preclinical and clinical, underscores the pivotal role of the extracellular matrix (ECM) in modulating immune cell infiltration and behaviors. This study aimed to create an innovative classifier that leverages ECM characteristics to enhance the effectiveness of ICB therapy.

Methods

We analyzed transcriptomic collagen activity and immune signatures in 649 patients with cancer undergoing ICB therapy. This analysis led to the identification of three distinct immuno‐collagenic subtypes predictive of ICB responses. We validated these subtypes using the transcriptome data from 9,363 cancer patients from The Cancer Genome Atlas (TCGA) dataset and 1,084 in‐house samples. Additionally, novel therapeutic targets were identified based on these established immuno‐collagenic subtypes.

Results

Our categorization divided tumors into three subtypes: “soft & hot” (low collagen activity and high immune infiltration), “armored & cold” (high collagen activity and low immune infiltration), and “quiescent” (low collagen activity and immune infiltration). Notably, “soft & hot” tumors exhibited the most robust response to ICB therapy across various cancer types. Mechanistically, inhibiting collagen augmented the response to ICB in preclinical models. Furthermore, these subtypes demonstrated associations with immune activity and prognostic predictive potential across multiple cancer types. Additionally, an unbiased approach identified B7 homolog 3 (B7‐H3), an available drug target, as strongly expressed in “armored & cold” tumors, relating with poor prognosis.

Conclusion

This study introduces histopathology‐based universal immuno‐collagenic subtypes capable of predicting ICB responses across diverse cancer types. These findings offer insights that could contribute to tailoring personalized immunotherapeutic strategies for patients with cancer.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Immune Checkpoint InhibitorsNeoplasmsCollagenHumansTumor MicroenvironmentAnimalsBiomarkers, TumorExtracellular MatrixMiceTranscriptomeFemalePrognosis

Stichwörter der Autor:innen

collagen depositionimmune infiltrationimmunotherapypan‐cancertumor microenvironment

Substanzen

Immune Checkpoint InhibitorsCollagenBiomarkers, Tumor

Autor:innen und Institutionen

  • Department of Oncology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu, P. R. China.
  • The First Clinical Medicine College, Nanjing Medical University, Nanjing, Jiangsu, P. R. China.
  • Departments of Gynecology, Wuxi Maternal and Child Health Care Hospital, Wuxi Medical Center, Nanjing Medical University, Wuxi, Jiangsu, P. R. China.
  • Departments of Oncology, Xuzhou Central Hospital, The Xuzhou School of Clinical Medicine of Nanjing Medical University, Xuzhou, Jiangsu, P. R. China.
  • Department of Sports Medicine, Huashan Hospital Affiliated to Fudan University, Shanghai, P. R. China.
  • Department of Sports Medicine, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, P. R. China.

ORCID-Profile: Jie Mei, Yunlong Yang, Yan Zhang, Yongmei Yin

Förderung

  • National Key Research and Development Program of China
  • National Natural Science Foundation of China
  • High-level Innovation Team of Nanjing Medical University
  • Precision Medicine Project of Wuxi Municipal Health Commission
  • Project of Wuxi Medical Center of Nanjing Medical University

Zitieren

APA

Mei, J., Cai, Y., Xu, R., Li, Q., Chu, J., Luo, Z., Sun, Y., Shi, Y., Xu, J., Li, D., Liang, S., Jiang, Y., Liu, J., Qian, Z., Zhou, J., Wan, M., Yang, Y., Zhu, Y., Zhang, Y., & Yin, Y. (2024). Conserved immuno‐collagenic subtypes predict response to immune checkpoint blockade. Cancer Communications. https://doi.org/10.1002/cac2.12538

Vancouver

Mei J, Cai Y, Xu R, Li Q, Chu J, Luo Z, et al. Conserved immuno‐collagenic subtypes predict response to immune checkpoint blockade. Cancer Communications. 2024. doi:10.1002/cac2.12538

BibTeX
@article{Mei2024,
  author = {Mei, Jie and Cai, Yun and Xu, Rui and Li, Qing and Chu, Jiahui and Luo, Zhiwen and Sun, Yaying and Shi, Yuxin and Xu, Junying and Li, Di and Liang, Shuai and Jiang, Ying and Liu, Jiayu and Qian, Zhiwen and Zhou, Jiaofeng and Wan, Mengyun and Yang, Yunlong and Zhu, Yichao and Zhang, Yan and Yin, Yongmei},
  title = {Conserved immuno‐collagenic subtypes predict response to immune checkpoint blockade},
  journal = {Cancer Communications},
  year = {2024},
  doi = {10.1002/cac2.12538}
}
Kostenlos starten →